SOURCE: Agendia B.V.

June 13, 2007 02:00 ET

Agendia Appoints Dr. Jan Groen as Chief Operating Officer

AMSTERDAM, THE NETHERLANDS--(Marketwire - June 13, 2007) - Agendia B.V. has appointed Dr. Jan Groen as Chief Operating Officer (COO) of the company. In his new position Dr. Groen will direct Agendia's daily operations.

Dr. Groen has more than 25 years experience in the clinical diagnostic industry, including product development, clinical trials and laboratory operations. Prior to joining Agendia B.V., Dr. Groen served as Vice President Research and Development for Focus Diagnostics Inc. (a subsidiary of Quest Diagnostics Corp.) in California, Co-founder and R&D Director for ViroClinics B.V., Virologist at the Erasmus Medical Center in Rotterdam and several managerial positions at the National Institute of public Health and Environmental Protection in Bilthoven, The Netherlands.

"Dr. Groen's track record within the clinical diagnostic market and his organizational skills makes him ideally suited to execute our plans for growth," states Dr. Bernhard Sixt, Chief Executive Officer.

Dr. Groen stated, "Agendia has all the right components for near future success with two exciting products on the market, MammaPrint and CupPrint, its quality certified field-proven technology, and exciting new products in the pipeline. The recent FDA approval of MammaPrint and Agendia's plans for expanding its offering to US patients in the near future is of particular appeal."

About Agendia

Agendia is a world leader in gene expression analysis-based diagnostics. The company focuses on the development and commercialization of diagnostic tests using tumor gene expression profiling. Agendia was the first to commercialize a prognostic test -- MammaPrint® -- that predicts the chance of breast cancer recurrence. CupPrint®, the second product in the market of Agendia, is used for the identification of Cancers of Unknown Primary. Agendia maintains close ties with NKI/AVL, ensuring access to the latest developments in cancer research. Apart from the development of new cancer diagnostics, Agendia offers its expertise in finding new predictive gene expression profiles to companies focusing on new drug development in the area of oncology.

More information about Agendia B.V. is available at

Contact Information

    Dr. Bernhard Sixt
    CEO of Agendia
    tel: +31-20-5129161
    Email Contact